Insights & Analysis
Practical guidance on PBM audits, federal investigations, compounding defense, DEA enforcement, telehealth compliance, and the regulatory pressures facing pharmacies and providers nationwide.
More articles — Page 13
Page 13 of 18 · 159 articles
Corporate Advice: Asset Deals – Advantages & Disadvantages
In the final Part Three of a three-part series on corporate transactions, we describe important considerations around structuring…
Express Scripts FWA Investigative Alert: Crackdown on CoverMyMeds Provider Accounts
Express Scripts is targeting prior authorization Fraud, Waste & Abuse involving the use of CoverMyMeds provider accounts by pharma…
Increased Scrutiny for DEA Registration Applications
DEA registration applications are receiving increased scrutiny as DEA turns its sights on providers and pharmacies to curtail cont…
Corporate Advice: Stock Deals – Advantages & Disadvantages
In Part Two of a three-part series on corporate transactions, we describe important considerations around structuring the sale of…
Medicare Advantage Cuts to Increase PBM Pressures
Insurers have bet big on Medicare Advantage, but the government is slowly cutting back. Faced with rising medical loss ratios and…
OTC Enforcement Update and PBM Audit Alert
On the heels of federal criminal investigations into OTC card usage, payors are now auditing OTC processes and imposing severe san…
Pharmacy Alert: Texas Board of Pharmacy Investigations
Texas pharmacies are facing increasing scrutiny by the Board of Pharmacy, which is working closely with the DEA and other federal…
Safeguarding Independents: HLA Reverses PBM Termination on Appeal
PBMs are huge companies that often use their market power in an abusive and predatory manner. This case study and successful netwo…
Corporate Advice: Asset Deals vs. Stock Deals
In Part One of a three-part series on corporate transactions, we describe preliminary considerations around deal structure. In sub…